Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | ERN1 | O75460 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL364414 | 0.82 | NFE2L2 (0.48) | SRCERN1ALDH1A1CYP2A6NFE2L2 | |
| SCHEMBL17586863 | 0.82 | NFE2L2 (0.48) | SRCERN1ALDH1A1CYP2A6NFE2L2 | |
| SCHEMBL29937373 | 0.82 | NFE2L2 (0.48) | SRCERN1ALDH1A1CYP2A6NFE2L2 | |
| SCHEMBL18255048 | 0.79 | NFE2L2 (0.40) | SRCERN1ALDH1A1NFE2L2 | |
| SCHEMBL6977265 | 0.79 | ERN1 (0.46) | ERN1 | |
| SCHEMBL2888296 | 0.78 | ERN1 (0.52) | SRCERN1ALDH1A1CYP2A6KDM4E | |
| SCHEMBL23557708 | 0.78 | ALDH1A1 (0.40) | SRCERN1ALDH1A1NFE2L2KDM4E | |
| SCHEMBL16950983 | 0.77 | NFE2L2 (0.41) | SRCALDH1A1CYP2A6NFE2L2KDM4E | |
| SCHEMBL4598520 | 0.77 | NFE2L2 (0.41) | SRCALDH1A1CYP2A6NFE2L2KDM4E | |
| SCHEMBL17103491 | 0.77 | NFE2L2 (0.41) | SRCALDH1A1CYP2A6NFE2L2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114409595-A | 1-styryl isoquinoline derivative and preparation and application thereof | 南华大学附属第一医院 | 2022-04-29 | — | — | CN | claimed |
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | claimed |
| CN-111265512-A | Composition containing a mixture of benzyl benzene derivatives and uses thereof | 黄泳华 | 2020-06-12 | — | — | CN | claimed |
| CN-1558898-A | Antiviral agent | ��Ұ����ҩ��ʽ���� | 2004-12-29 | — | — | CN | claimed |
| EP-1422218-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2004-05-26 | — | — | EP | claimed |
| EP-4736855-A2 | TETRAHYDROPYRAN (THP)-SUBSTITUTED BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| EP-4464321-B1 | TETRAHYDROPYRAN (THP)-SUBSTITUTED BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4626891-A1 | FUSED PYRIMIDINES AS MASP-2 INHIBITORS | Omeros Corporation (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20250282779-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | MYOKARDIA INC (US) | 2025-09-11 | — | — | US | disclosed |
| US-12344607-B2 | Substituted 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4-diones for treating cardiac diseases | MyoKardia, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| CN-119977963-A | Tetrahydropyrane (THP) -substituted bicyclic pyrimidinedione compounds | 迈奥卡迪亚公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-1997009308-A1 | INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-03-13 | — | — | WO | disclosed |
| EP-0116323-B1 | PROCESS FOR THE PRODUCTION OF AROMATIC ALDEHYDES | BAYER AG (DE) | 1986-08-20 | — | — | EP | disclosed |
| US-4588844-A | Process for preparing aromatic aldehydes | BAYER AKTIENGESELLSCHAFT (DE) | 1986-05-13 | — | — | US | disclosed |
| EP-0116323-A1 | Process for the production of aromatic aldehydes | BAYER AG (DE) | 1984-08-22 | — | — | EP | disclosed |
| US-4224340-A | Anti-inflammatory compositions containing α-phenyl-N-phenylnitrone compounds | WILLIAM H. RORER, INC. (US) | 1980-09-23 | — | — | US | disclosed |
| US-4214003-A | ANTIINFLAMMATORY AGENTS | WILLIAM H. RORER, INC. (US) | 1980-07-22 | — | — | US | disclosed |
| US-4197314-A | WITH A DIPHENYL NITRONE | WILLIAM H. RORER, INC. (US) | 1980-04-08 | — | — | US | disclosed |
| US-4153722-A | ANTIINFLAMMATORY, A-PHENYL-N-PHENYLNITRONE | WILLIAM H. RORER, INC. (US) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282779-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | DHPS, THPO, TNNI3 | SRC 3184/4885ERN1 1415/4885ALDH1A1 2173/4885 |
| US-20260035341-A1 | FTO INHIBITORS | FTO, LDLR, GPR119 | SRC 637/4885ERN1 1140/4885ALDH1A1 1334/4885 |
| US-12344607-B2 | Substituted 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4-diones for treating cardiac diseases | DHPS, THPO, TNNI3 | SRC 2947/4885ERN1 1485/4885ALDH1A1 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.